Teleflex Incorporated, a recognized global leader in medical technologies, recently conducted a multinational study on its Arrow™ Chlorhexidine-Impregnated Central Venous Catheters (CVCs). The study results lend substantial clinical validation to the product, revealing an impressive 70.5% reduction in CLABSI (central line-associated bloodstream infections) – a percentage derived from a robust sample size of more than 6,670 patients in twelve ICUs across eight different countries.
Notably, the catheters performed exceptionally well in combating infections despite their usage in patient cases marked by prolonged ICU stays and higher device utilization ratios, factors typically associated with heightened infection risk. The study was conducted ensuring homogeneous catheter insertion training and barrier precautions across all operations, thereby eliminating technique variability.
An insightful aspect of the study was its identification of unprotected CVCs as a potential independent risk factor for infection. This points towards the significant role catheter technology could play in preventing infection, even with impeccable insertion techniques and barrier precautions. The findings, therefore, underscore the clinical efficacy of Teleflex’s antimicrobial technology, providing substantial proof which healthcare professionals and stakeholders may view as a huge step-forward in the reduction of hospital-acquired infections and associated burdens, such as cost, extended hospital stays, and mortality risks.
The study also reported a reduced frequency of critical pathogens in the antimicrobial catheters including gram-negative bacteria (E.g., Klebsiella pneumoniae, Pseudomonas aeruginosa, Escherichia coli), gram-positive bacteria (E.g., Staphylococcus aureus, Enterococcus faecium), and fungi (such as Candida species). These findings position the product as a potentially crucial component of CLABSI prevention protocol regimens in healthcare settings.
Dr. Amy Bardin, Vice President of Clinical and Medical Affairs at Teleflex, corroborated the strength of these data, emphasizing that even high adherence to best practices during CVC insertion couldn’t fully counteract CLABSI. The study’s discovery of higher incidence rates of various pathogens in patients with ordinary CVCs further cements the effectiveness of Chlorhexidine on Arrow™ CVCs.
Teleflex remains committed to pushing the boundaries in healthcare innovation, and these study results align with that mission. The company anticipates that these findings will shape the future direction of healthcare, offering improved patient outcomes, possible revolution in CLABSI prevention protocols, and an overall augmentation in the quality of healthcare services.